• Sensorion will present preclinical gene therapy research at the European Society of Gene & Cell Therapy congress in Hamburg, October 27-30, 2026.
• An October 28 poster will cover laboratory assessment of functional gap junctions for a GJB2 gene therapy targeting inherited deafness.
• An October 29 presentation will focus on SENS-601, its lead gene therapy program targeting hearing loss linked to GJB2 mutations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensorion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202610280230BIZWIRE_USPR_____20261027_BW238416) on October 28, 2026, and is solely responsible for the information contained therein.